Oncology Drug Snapshot: Axitinib (Inlyta)

Article

This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Recent Videos
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
Related Content
Allogeneic CAR-T Azer-Cel Achieves Complete Responses in Some Patients With Diffuse Large B-Cell Lymphoma

Allogeneic CAR-T Azer-Cel Achieves Complete Responses in Some Patients With Diffuse Large B-Cell Lymphoma

Noah Stansfield
September 10th 2024
Article

The cell therapy, originally developed by Precision BioSciences, is being evaluated for LBCL by Imugene.

Lisa Nieland, a PhD candidate from Lieden University Medical Center and Breakefield Lab at Mass Gen

Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy

Lisa Nieland;Noah Stansfield
September 10th 2024
Article

Lisa Nieland, a PhD candidate from Lieden University Medical Center and Breakefield Lab at Mass Gen, discussed her work presented at the ASGCT 2024 meeting.

Solid Biosciences Tracking Long-Term Effects of Duchenne Muscular Dystrophy Gene Therapy in Phase 1/2 IGNITE-DMD Study

Solid Biosciences Tracking Long-Term Effects of Duchenne Muscular Dystrophy Gene Therapy in Phase 1/2 IGNITE-DMD Study

Noah Stansfield
September 9th 2024
Article

Following up on World Duchenne Awareness Day, observed annually on September 7 by the clinician and patient communities, CGTLive® has decided to take a closer look at this study.

Higher-Dose Nusinersen Boasts 6-Month Motor Improvement in Spinal Muscular Atrophy

Higher-Dose Nusinersen Boasts 6-Month Motor Improvement in Spinal Muscular Atrophy

Isabella Ciccone, MPH
September 9th 2024
Article

Biogen plans to submit for regulatory approval for a higher dose based on the positive topline data from the phase 2/3 DEVOTE study (NCT04089566).

Real-World Experience With Duchenne Muscular Dystrophy Gene Therapy

Real-World Experience With Duchenne Muscular Dystrophy Gene Therapy

Noah Stansfield;Isabella Ciccone, MPH
September 7th 2024
Article

In honor of World Duchenne Awareness Day, held September 7, several experts have provided their insights on the real-world experience of gene therapy’s use in Duchenne muscular dystrophy.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – September 6, 2024

CGTLive Staff
September 6th 2024
Article

Review top news and interview highlights from the week ending September 6, 2024.

© 2024 MJH Life Sciences

All rights reserved.